Brokerages Set The Clorox Company (NYSE:CLX) Price Target at $117.93

The Clorox Company (NYSE:CLX) has been assigned a consensus recommendation of “Reduce” from the sixteen ratings firms that are covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $117.9333.

CLX has been the topic of a number of research analyst reports. Weiss Ratings downgraded shares of Clorox from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday. Zacks Research raised shares of Clorox from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. JPMorgan Chase & Co. upped their price target on shares of Clorox from $114.00 to $117.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Citigroup increased their price target on Clorox from $109.00 to $115.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, Jefferies Financial Group reduced their price objective on Clorox from $152.00 to $151.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th.

Clorox Trading Up 1.6%

Shares of CLX stock opened at $119.52 on Friday. Clorox has a fifty-two week low of $96.66 and a fifty-two week high of $159.04. The stock’s fifty day moving average price is $105.83 and its two-hundred day moving average price is $113.73. The company has a debt-to-equity ratio of 71.03, a quick ratio of 0.48 and a current ratio of 0.74. The company has a market cap of $14.45 billion, a PE ratio of 19.53, a P/E/G ratio of 0.59 and a beta of 0.59.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $1.39 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.04). The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.64 billion. Clorox had a return on equity of 383.01% and a net margin of 11.17%.Clorox’s quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the firm posted $1.55 EPS. Equities analysts predict that Clorox will post 7.15 EPS for the current fiscal year.

Clorox Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Wednesday, January 28th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 4.1%. The ex-dividend date is Wednesday, January 28th. Clorox’s payout ratio is 81.05%.

More Clorox News

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Morgan Stanley raised its price target on CLX to $136 (maintained equal-weight), citing valuation/earnings dynamics — a catalyst supporting the stock’s rally. Clorox (NYSE:CLX) Price Target Raised to $136.00 at Morgan Stanley
• Positive Sentiment: Investor write-ups are bullish: a Seeking Alpha piece frames CLX as a defensive, dividend-rich value after “solid” Q2 results and attractive valuation — supporting buy interest from income-focused investors. Clorox: Solid Q2 Results And Cheap Valuation MakesThis Defensive Dividend Stock A Strong Buy
• Neutral Sentiment: TD Cowen nudged its price target to $111 and kept a Hold rating — a modest recalibration that tempers upside expectations despite the recent positive headlines. TD Cowen Adjusts Clorox Price Target
• Neutral Sentiment: Company reported mixed Q2 results and reaffirmed its 2026 outlook — revenue roughly flat year-over-year and an EPS miss by a few cents; reassurances on the outlook limit downside but leave questions on near-term margin recovery. Clorox Posts Mixed Q2 Results, Reaffirms 2026 Outlook
• Neutral Sentiment: Management is weighing a potential GOJO acquisition and finishing an ERP implementation; strategic moves could boost long-term growth but add execution risk in the near term. Clorox Weighs GOJO Deal And ERP Finish Against Softer Earnings
• Neutral Sentiment: Q2 earnings call transcript is available for deeper read on management commentary around pricing, cost savings and margin plans — useful for gauging execution risk. Clorox (CLX) Q2 2026 Earnings Call Transcript
• Negative Sentiment: Some brokerages have a consensus “Reduce” rating on CLX, which may cap upside as institutional flows react to conservative guidance and margin concerns. The Clorox Company Given Consensus Rating of “Reduce” by Brokerages
• Negative Sentiment: BofA flagged margin uncertainty after the Q2 EPS miss — a reminder that cost and margin recovery, not just revenue, will drive forecast revisions and investor sentiment. BofA Flags Margin Uncertainty for Clorox After Q2 Earnings Miss
• Neutral Sentiment: A Zacks piece highlights using its Earnings ESP tool to find staples stocks that might beat — general market research, not CLX-specific guidance, but could affect short-term trading interest. Why Investors Need to Take Advantage of These 2 Consumer Staples Stocks Now

Insider Activity

In other news, Director Pierre R. Breber acquired 4,000 shares of the stock in a transaction dated Friday, November 21st. The stock was bought at an average price of $104.13 per share, with a total value of $416,520.00. Following the completion of the purchase, the director directly owned 13,000 shares of the company’s stock, valued at $1,353,690. This represents a 44.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.63% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Clorox

Institutional investors have recently added to or reduced their stakes in the business. Center for Financial Planning Inc. bought a new position in shares of Clorox during the third quarter valued at $25,000. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Clorox in the third quarter worth $25,000. Total Investment Management Inc. acquired a new stake in Clorox in the second quarter valued at $25,000. True Wealth Design LLC raised its position in Clorox by 1,020.0% during the 3rd quarter. True Wealth Design LLC now owns 224 shares of the company’s stock worth $28,000 after purchasing an additional 204 shares during the last quarter. Finally, NewSquare Capital LLC raised its position in Clorox by 567.6% during the 2nd quarter. NewSquare Capital LLC now owns 227 shares of the company’s stock worth $27,000 after purchasing an additional 193 shares during the last quarter. 78.53% of the stock is owned by institutional investors.

About Clorox

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.